<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="aogs14654" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Acta Obstet Gynecol Scand</journal-id><journal-id journal-id-type="iso-abbrev">Acta Obstet Gynecol Scand</journal-id><journal-id journal-id-type="pmc-domain-id">4315</journal-id><journal-id journal-id-type="pmc-domain">aogs</journal-id><journal-id journal-id-type="publisher-id">AOGS</journal-id><journal-title-group><journal-title>Acta Obstetricia et Gynecologica Scandinavica</journal-title></journal-title-group><issn pub-type="ppub">0001-6349</issn><issn pub-type="epub">1600-0412</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10993328</article-id><article-id pub-id-type="pmcid-ver">PMC10993328.1</article-id><article-id pub-id-type="pmcaid">10993328</article-id><article-id pub-id-type="pmcaiid">10993328</article-id><article-id pub-id-type="pmid">37578024</article-id><article-id pub-id-type="doi">10.1111/aogs.14654</article-id><article-id pub-id-type="publisher-id">AOGS14654</article-id><article-id pub-id-type="other">AOGS-23-0223.R3</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Research Articles</subject></subj-group></article-categories><title-group><article-title>Contraception and sterilization selection at delivery among pregnant patients with malignancy</article-title><alt-title alt-title-type="left-running-head">Harris et al.</alt-title></title-group><contrib-group><contrib id="aogs14654-cr-0001" contrib-type="author"><name name-style="western"><surname>Harris</surname><given-names initials="CA">Chelsey A.</given-names></name><xref rid="aogs14654-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="aogs14654-cr-0002" contrib-type="author"><name name-style="western"><surname>Mandelbaum</surname><given-names initials="RS">Rachel S.</given-names></name><xref rid="aogs14654-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="aogs14654-cr-0003" contrib-type="author"><name name-style="western"><surname>Rau</surname><given-names initials="AR">Alesandra R.</given-names></name><xref rid="aogs14654-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aogs14654-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="aogs14654-cr-0004" contrib-type="author"><name name-style="western"><surname>Song</surname><given-names initials="BB">Bonnie B.</given-names></name><xref rid="aogs14654-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="aogs14654-cr-0005" contrib-type="author"><name name-style="western"><surname>Klar</surname><given-names initials="M">Maximilian</given-names></name><xref rid="aogs14654-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="aogs14654-cr-0006" contrib-type="author"><name name-style="western"><surname>Ouzounian</surname><given-names initials="JG">Joseph G.</given-names></name><xref rid="aogs14654-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="aogs14654-cr-0007" contrib-type="author"><name name-style="western"><surname>Paulson</surname><given-names initials="RJ">Richard J.</given-names></name><xref rid="aogs14654-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="aogs14654-cr-0008" contrib-type="author"><name name-style="western"><surname>Roman</surname><given-names initials="LD">Lynda D.</given-names></name><xref rid="aogs14654-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aogs14654-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="aogs14654-cr-0009" contrib-type="author" corresp="yes"><name name-style="western"><surname>Matsuo</surname><given-names initials="K">Koji</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6232-8701</contrib-id><xref rid="aogs14654-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aogs14654-aff-0006" ref-type="aff">
<sup>6</sup>
</xref><address><email>koji.matsuo@med.usc.edu</email></address></contrib></contrib-group><aff id="aogs14654-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Division of Gynecologic Oncology, Department of Obstetrics and Gynecology</named-content>
<institution>University of Southern California</institution>
<city>Los Angeles</city>
<named-content content-type="country-part">California</named-content>
<country country="US">USA</country>
</aff><aff id="aogs14654-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology</named-content>
<institution>University of Southern California</institution>
<city>Los Angeles</city>
<named-content content-type="country-part">California</named-content>
<country country="US">USA</country>
</aff><aff id="aogs14654-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Keck School of Medicine</named-content>
<institution>University of Southern California</institution>
<city>Los Angeles</city>
<named-content content-type="country-part">California</named-content>
<country country="US">USA</country>
</aff><aff id="aogs14654-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Obstetrics and Gynecology, Faculty of Medicine</named-content>
<institution>University of Freiburg Medical Center</institution>
<city>Freiburg</city>
<country country="DE">Germany</country>
</aff><aff id="aogs14654-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Division of Maternal&#8208;Fetal Medicine, Department of Obstetrics and Gynecology</named-content>
<institution>University of Southern California</institution>
<city>Los Angeles</city>
<named-content content-type="country-part">California</named-content>
<country country="US">USA</country>
</aff><aff id="aogs14654-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Norris Comprehensive Cancer Center</named-content>
<institution>University of Southern California</institution>
<city>Los Angeles</city>
<named-content content-type="country-part">California</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Koji Matsuo, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, 2020 Zonal Avenue, IRD520, Los Angeles, CA 90033, USA.<break/>
Email: <email>koji.matsuo@med.usc.edu</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>8</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2024</year></pub-date><volume>103</volume><issue seq="100">4</issue><issue-id pub-id-type="pmc-issue-id">459386</issue-id><issue-id pub-id-type="doi">10.1111/aogs.v103.4</issue-id><issue-title>CANCER DURING PREGNANCY</issue-title><fpage>695</fpage><lpage>706</lpage><history><date date-type="rev-recd"><day>06</day><month>7</month><year>2023</year></date><date date-type="received"><day>24</day><month>3</month><year>2023</year></date><date date-type="accepted"><day>12</day><month>7</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>14</day><month>08</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>05</day><month>04</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-04-05 10:25:16.017"><day>05</day><month>04</month><year>2024</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2023 The Authors. <italic toggle="yes">Acta Obstetricia et Gynecologica Scandinavica</italic> published by John Wiley &amp; Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG).</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="AOGS-103-695.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:AOGS-103-695.pdf"/><abstract><title>Abstract</title><sec id="aogs14654-sec-0001"><title>Introduction</title><p>Since malignancy during pregnancy is uncommon, information regarding contraception selection or sterilization at delivery is limited. The objective of this study was to examine the type of long&#8208;acting reversible contraception or surgical sterilization procedure chosen by pregnant patients with malignancy at delivery.</p></sec><sec id="aogs14654-sec-0002"><title>Material and methods</title><p>This cross&#8208;sectional study queried the Healthcare Cost and Utilization Project's National Inpatient Sample in the USA. The study population was vaginal and cesarean deliveries in a hospital setting from January 2017 to December 2020. Pregnant patients with breast cancer (<italic toggle="no">n</italic>&#8201;=&#8201;1605), leukemia (<italic toggle="no">n</italic>&#8201;=&#8201;1190), lymphoma (<italic toggle="no">n</italic>&#8201;=&#8201;1120), thyroid cancer (<italic toggle="no">n</italic>&#8201;=&#8201;715), cervical cancer (<italic toggle="no">n</italic>&#8201;=&#8201;425) and melanoma (<italic toggle="no">n</italic>&#8201;=&#8201;400) were compared with 14&#8201;265&#8201;319 pregnant patients without malignancy. The main outcome measures were utilization of long&#8208;acting reversible contraception (subdermal implant or intrauterine device) and performance of permanent surgical sterilization (bilateral tubal ligation or bilateral salpingectomy) during the index hospital admission for delivery, assessed with a multinomial regression model controlling for clinical, pregnancy and delivery characteristics.</p></sec><sec id="aogs14654-sec-0003"><title>Results</title><p>When compared with pregnant patients without malignancy, pregnant patients with breast cancer were more likely to proceed with bilateral salpingectomy (adjusted odds ratio [aOR] 2.30) or intrauterine device (aOR 1.91); none received the subdermal implant. Pregnant patients with leukemia were more likely to choose a subdermal implant (aOR 2.22), whereas those with lymphoma were more likely to proceed with bilateral salpingectomy (aOR 1.93) and bilateral tubal ligation (aOR 1.76). Pregnant patients with thyroid cancer were more likely to proceed with bilateral tubal ligation (aOR 2.21) and none received the subdermal implant. No patients in the cervical cancer group selected long&#8208;acting reversible contraception, and they were more likely to proceed with bilateral salpingectomy (aOR 2.08). None in the melanoma group chose long&#8208;acting reversible contraception. Among pregnant patients aged &lt;30, the odds of proceeding with bilateral salpingectomy were increased in patients with breast cancer (aOR 3.01), cervical cancer (aOR 2.26) or lymphoma (aOR 2.08). The odds of proceeding with bilateral tubal ligation in pregnant patients aged &lt;30 with melanoma (aOR 5.36) was also increased.</p></sec><sec id="aogs14654-sec-0004"><title>Conclusions</title><p>The results of this nationwide assessment in the United States&#160;suggest that among pregnant patients with malignancy, the preferred contraceptive option or method of sterilization at time of hospital delivery differs by malignancy type.</p></sec></abstract><abstract abstract-type="graphical"><p>The Healthcare Cost and Utilization Project's National Inpatient Sample was examined to assess contraceptive use and surgical sterilization choice at in&#8208;hospital delivery. The results suggest that among pregnant patients with malignancy, the preferred contraceptive option or method of sterilization at time of hospital delivery differs by malignancy type.<boxed-text position="anchor" content-type="graphic" id="aogs14654-blkfxd-0001" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="AOGS-103-695-g001.jpg"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="aogs14654-kwd-0001">cancer</kwd><kwd id="aogs14654-kwd-0002">contraception</kwd><kwd id="aogs14654-kwd-0003">delivery</kwd><kwd id="aogs14654-kwd-0004">malignancy</kwd><kwd id="aogs14654-kwd-0005">pregnancy</kwd><kwd id="aogs14654-kwd-0006">sterilization</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>Ensign Endowment for Gynecologic Cancer Research</funding-source></award-group></funding-group><counts><fig-count count="2"/><table-count count="6"/><page-count count="12"/><word-count count="6135"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2024</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.4.0 mode:remove_FC converted:04.04.2024</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="AOGS14654-cit-2001"><string-name name-style="western"><surname>Harris</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Mandelbaum</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Rau</surname><given-names>AR</given-names></string-name>, et al. <article-title>Contraception and sterilization selection at delivery among pregnant patients with malignancy</article-title>. <source>Acta Obstet Gynecol Scand</source>. <year>2024</year>;<volume>103</volume>:<fpage>695</fpage>&#8208;<lpage>706</lpage>. doi:<pub-id pub-id-type="doi">10.1111/aogs.14654</pub-id><pub-id pub-id-type="pmcid">PMC10993328</pub-id><pub-id pub-id-type="pmid">37578024</pub-id></mixed-citation>
</p></notes></front><body id="aogs14654-body-0001"><def-list list-content="abbreviations" id="aogs14654-dl-0001"><title>Abbreviations</title><def-item><term id="aogs14654-li-0001">aOR</term><def id="aogs14654-li-0002"><p>adjusted odds ratio</p></def></def-item><def-item><term id="aogs14654-li-0003">BTL</term><def id="aogs14654-li-0004"><p>bilateral tubal ligation</p></def></def-item><def-item><term id="aogs14654-li-0005">ICD&#8208;10</term><def id="aogs14654-li-0006"><p>International Classification of Disease 10th edition</p></def></def-item><def-item><term id="aogs14654-li-0007">IUD</term><def id="aogs14654-li-0008"><p>intrauterine device</p></def></def-item><def-item><term id="aogs14654-li-0009">LARC</term><def id="aogs14654-li-0010"><p>long&#8208;acting reversible contraction</p></def></def-item></def-list><p>
<boxed-text position="anchor" content-type="box" id="aogs14654-blkfxd-0002" orientation="portrait"><caption><title>Key message</title></caption><p>Among pregnant patients with malignancy, the preferred contraceptive option or method of sterilization at time of hospital delivery differs across malignancy type.</p></boxed-text>
</p><sec id="aogs14654-sec-0007"><label>1</label><title>INTRODUCTION</title><p>Women have a 5.8% chance of developing invasive cancer by age 49&#8201;years.<xref rid="aogs14654-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> The present cohort includes a subset of reproductive age women who may become pregnant with a diagnosis of cancer, or develop cancer during a pregnancy. Family planning in this population is paramount and will require specialized counseling and provider advocacy.<xref rid="aogs14654-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="aogs14654-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> The U.S. Medical Eligibility Criteria for Contraceptive Use is an excellent resource for providers, providing recommendations on safe contraceptive methods for a myriad of conditions including cervical, endometrial, breast, ovarian and liver cancer;<xref rid="aogs14654-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> however, other common cancers in this age group are not addressed.</p><p>Between 2016 and 2019, pregnant women with cancer accounted for approximately 70 per 100&#8201;000 deliveries in the USA.<xref rid="aogs14654-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> A similar incidence, 89.6 per 100&#8201;000 pregnancies, was seen in Denmark between 1997 and 2006,<xref rid="aogs14654-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> and a slightly higher incidence, 112&#8211;191 per 100&#8201;000 deliveries, was seen in Australia between 1994 and 2007.<xref rid="aogs14654-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> While it is still fairly uncommon worldwide, these figures are expected to rise due in some part to advancing maternal age.<xref rid="aogs14654-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>
</p><p>There has been some focus on the ethical dilemma of offering cancer treatment before or during pregnancy.<xref rid="aogs14654-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="aogs14654-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> Anti&#8208;cancer treatments such as systemic chemotherapy will significantly increase the risk of fetal anomaly, growth restriction and prematurity during pregnancy, and infertility and ovarian aging before pregnancy. Patient fertility goals will vary based on individualized disease characteristics, underscoring the unique contraceptive counseling needs of this cohort relative to the general population.</p><p>The most efficacious options include long&#8208;acting reversible contraception (LARC) and surgical sterilization via bilateral salpingectomy or bilateral tubal ligation (BTL). In the general population, the incidence of inpatient postpartum LARC placement is increasing, whereas inpatient postpartum sterilization is decreasing.<xref rid="aogs14654-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Additionally, female cancer survivors of reproductive age seem to have a lower rate of contraceptive use than found in the non&#8208;cancer population.<xref rid="aogs14654-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="aogs14654-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> Specifically, there are lower rates of Tier I&#8211;II contraceptive methods, which include surgical sterilization, subdermal implants, intrauterine device (IUD), pills, rings, patches and injectables.<xref rid="aogs14654-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="aogs14654-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>
</p><p>Less is known about contraceptive choices at the time of delivery made by pregnant patients with cancer. The objective of the current study was to examine the type of LARC or surgical sterilization procedure chosen by pregnant patients with a diagnosis of malignancy at the time of hospital delivery in the United States.</p></sec><sec sec-type="materials-and-methods" id="aogs14654-sec-0008"><label>2</label><title>MATERIAL AND METHODS</title><sec id="aogs14654-sec-0009"><label>2.1</label><title>Data</title><p>The Healthcare Cost and Utilization Project's National Inpatient Sample in the United States was retrospectively queried for this cross&#8208;sectional&#160;study.<xref rid="aogs14654-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> Their project is supported and distributed by the Agency for Healthcare Research and Quality. The program approximates a stratified sample of 20% of discharges in each center from all the participating hospitals across 48 States and the District of Columbia every year. By applying the survey weights, the National Inpatient Sample represents more than 97% of hospital discharge data in the US population. The University of Southern California Institutional Review Board exempted the current study from ethics approval due to the use of publicly available, deidentified data.</p></sec><sec id="aogs14654-sec-0010"><label>2.2</label><title>Study population</title><p>The study population included hospital&#8208;setting vaginal and cesarean deliveries between January 2017 and December 2020. The starting point was chosen due to the introduction of the World Health Organization's International Classification of Disease 10th revision (ICD&#8208;10) Clinical Modification code for subdermal implants (Table&#160;<xref rid="aogs14654-tbl-0001" ref-type="table">1</xref>).<xref rid="aogs14654-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> Identification of vaginal and cesarean deliveries followed the schema of prior studies (Table&#160;<xref rid="aogs14654-tbl-0001" ref-type="table">1</xref>).<xref rid="aogs14654-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="aogs14654-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="aogs14654-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> Patient age was limited to 15&#8211;54&#8201;years according to prior analyses.<xref rid="aogs14654-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="aogs14654-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>
</p><table-wrap position="float" id="aogs14654-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Coding schema.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Parameter</th><th align="left" valign="bottom" rowspan="1" colspan="1">ICD&#8208;10/DRG codes</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Vaginal delivery</td><td align="left" valign="top" rowspan="1" colspan="1">767, 768, 774, 775, 796, 797, 798, 805, 806, 807, O80, 10D07Z3, 10D07Z4, 10D07Z5, 10D07Z6, 10D07Z7, 10D07Z8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cesarean delivery</td><td align="left" valign="top" rowspan="1" colspan="1">765, 766, 783, 784, 785, 786, 787, 788, O82, O7582, 10D00Z0, 10D00Z1, 10D00Z2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Breast cancer</td><td align="left" valign="top" rowspan="1" colspan="1">C501&#8208;C509</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cervical cancer</td><td align="left" valign="top" rowspan="1" colspan="1">C530&#8208;C531, C538&#8208;C539</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Leukemia</td><td align="left" valign="top" rowspan="1" colspan="1">C910&#8208;C911, C913, C915&#8208;C916, C919, C91A, C91Z, C920&#8208;C926, C929, C92A, C92Z, C930&#8208;C931, C933, C939, C93Z, C944, C901, C914, C940, C942&#8208;C943, C948</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lymphoma</td><td align="left" valign="top" rowspan="1" colspan="1">C820&#8208;C826, C828&#8208;C829, C830&#8208;C831, C833, C835, C837&#8208;C839, C841, C844, C846, C847, C849, C84A, C84Z, C851&#8208;C852, C858&#8208;C859, C860&#8208;C866, C884, C810&#8208;C814, C817, C819</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Melanoma</td><td align="left" valign="top" rowspan="1" colspan="1">C430&#8208;C439</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Thyroid cancer</td><td align="left" valign="top" rowspan="1" colspan="1">C73</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Subdermal implant</td><td align="left" valign="top" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="Z30017">Z30017</ext-link></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Intrauterine device</td><td align="left" valign="top" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="Z30430">Z30430</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="Z30014">Z30014</ext-link>, OUH90HZ, OUH97HZ, OUH98HZ, OUHC7HZ, OUHC8HZ</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bilateral tubal ligation</td><td align="left" valign="top" rowspan="1" colspan="1">0U57, 0UL7, 0UF7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bilateral salpingectomy</td><td align="left" valign="top" rowspan="1" colspan="1">0UB7, 0UT7</td></tr></tbody></table></table-wrap></sec><sec id="aogs14654-sec-0011"><label>2.3</label><title>Inclusion and exclusion</title><p>Six common malignancy types among pregnant patients were preselected for the study based on prior investigations:<xref rid="aogs14654-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="aogs14654-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="aogs14654-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="aogs14654-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="aogs14654-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> breast cancer, leukemia, lymphoma, thyroid cancer, cervical cancer and melanoma. The rationale to examine these malignancies was as follows: (i) breast cancer was the most frequent malignancy during pregnancy followed by lymphoma and leukemia in a recent US study;<xref rid="aogs14654-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> (ii) melanoma was the most frequent malignancy during pregnancy followed by cervical cancer in a prior European study;<xref rid="aogs14654-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> and (iii) thyroid cancer was the second most common malignancy during pregnancy in prior US regional data.<xref rid="aogs14654-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>
</p><p>Identification of these malignancy types was based on the National Cancer Institute's definition (Table&#8201;<xref rid="aogs14654-tbl-0001" ref-type="table">1</xref>).<xref rid="aogs14654-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="aogs14654-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> The ICD&#8208;10 Clinical Modification codes do not specify the relative timing of cancer diagnosis and the index delivery. The non&#8208;malignancy group was defined as pregnant patients without any malignancy diagnoses, including the above identified six subtypes and other malignancies defined by the National Cancer Institute's definition.<xref rid="aogs14654-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="aogs14654-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>
</p><p>Across the six malignancy groups and the non&#8208;malignancy group, patients who had peripartum hysterectomy or who died during the index hospital admission for delivery were excluded from the analysis, as contraception or sterilization is not applicable for such a setting.</p></sec><sec id="aogs14654-sec-0012"><label>2.4</label><title>Outcome measures</title><p>The main outcome measures were utilization of LARC (subdermal implant or IUD) and performance of permanent surgical sterilization (BTL or bilateral salpingectomy) during the index hospital admission for delivery. Identification of these outcome measures was based on the ICD&#8208;10 Clinical Modification and Procedure Classification System codes that followed prior investigations (Table&#8201;<xref rid="aogs14654-tbl-0001" ref-type="table">1</xref>).<xref rid="aogs14654-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="aogs14654-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="aogs14654-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="aogs14654-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="aogs14654-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>
</p><p>Outcome measures were categorized mutually exclusively into the following: subdermal implant alone, IUD alone, BTL alone or bilateral salpingectomy alone, and none of LARC/surgical sterilization. Patients who had multiple outcome events, which occurred in 0.009% of cases, were excluded from the analysis, as a patient generally chooses only one of these four options.</p></sec><sec id="aogs14654-sec-0013"><label>2.5</label><title>Study covariates</title><p>The study covariates examined were pre&#8208;selected in a view of relevance to the exposure and outcomes. These included nine non&#8208;pregnancy factors, six pregnancy factors and five delivery factors (a total of 20 factors). The identification and classification of these study covariates followed prior studies.<xref rid="aogs14654-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="aogs14654-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="aogs14654-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> Cases with unknown status were grouped as one category in each study covariate.</p><p>Non&#8208;pregnancy factors included patient age (&lt;25, 25&#8211;29, 30&#8211;34 or&#8201;&#8805;35&#8201;years), year (2017, 2018, 2019 and 2020), race and ethnicity (White, Black, Hispanic and other) determined by the National Inpatient Sample program, primary payer (Medicaid, Private including HMO, and other), medical comorbidity (obesity, pregestational diabetes mellitus, pregestational hypertension), substance factor (tobacco use) and uterine factor (uterine myoma). Race and ethnicity were examined, as this factor is associated with pregnancy and delivery characteristics and outcomes. Primary payer and uterine factor were included, as these may affect LARC choice.</p><p>Pregnancy factors included fetal factors (multifetal gestation, intrauterine growth restriction and intrauterine fetal demise), infectious factor (chorioamnionitis) and maternal factors (gestational diabetes mellitus, gestational hypertension and preeclampsia). Fetal factors were included, as these may influence decisions regarding surgical sterilization. Infectious factor was considered, as it may influence IUD usage.</p><p>Delivery factors included gestational age (&#8805;37, 34&#8211;36 and&#8201;&lt;34&#8201;weeks&#8217; gestation), hospital location and teaching status (rural, urban non&#8208;teaching and urban teaching), hospital region in the USA (Northeast, Midwest, South and West), delivery route (vaginal or cesarean) and occurrence of severe maternal morbidity that followed the Centers for Disease Control and Prevention definition (a total of 21 indicators).<xref rid="aogs14654-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> Hospital parameters were included for possible hospital&#8208;level practice effects. Severe maternal morbidity was included, as this serious event at delivery may affect the decision to perform additional elective surgeries or procedures.</p></sec><sec id="aogs14654-sec-0014"><label>2.6</label><title>Analytic approach</title><p>The first step of analysis was to assess the clinical, pregnancy and delivery characteristics across the exposure to malignancy and non&#8208;malignancy groups. Kruskal&#8211;Wallis <italic toggle="yes">H</italic>&#8208;test was used to compare the median values across the exposure groups. Pearson's chi&#8208;square test was used to compare the proportion values across the exposure groups.</p><p>The second step of analysis was to assess the exposure&#8211;outcome association. Contraception and surgical sterilization selection among pregnant patients with malignancy were compared with those without malignancy. A multinomial regression model was fitted for this step analysis, and the exposure&#8211;outcome association was adjusted for clinical, pregnancy and delivery factors. Multicollinearity was assessed among the study covariates. The likelihood of contraception use and surgical sterilization was estimated by malignancy type with adjusted odds ratio (aOR) and a corresponding 95% confidence interval (CI).</p><p>Various sensitivity analyses were undertaken to assess the robustness of the study findings. First, exposure&#8211;outcome associations were assessed per patient age (&#8805;30 or&#8201;&lt;30&#8201;years). This age cutoff was the estimated age of second childbirth, extrapolated from the average age of first childbirth (27.0&#8201;years) and the average time interval from first to second childbirth (2.4&#8201;years).<xref rid="aogs14654-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>, <xref rid="aogs14654-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>
</p><p>Secondly, outcome measures were examined according to the route of delivery (cesarean or vaginal). This was based on the notion that patients in an unselected population were more likely to choose surgical sterilization when proceeding with cesarean delivery in the USA.<xref rid="aogs14654-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>
</p><p>Thirdly, the exposure&#8211;outcome association was assessed according to race (white or non&#8208;white), as prior studies suggested that patient's choice for LARC and surgical sterilization may differ based on this.<xref rid="aogs14654-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="aogs14654-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="aogs14654-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>
</p><p>Lastly, cases with an unknown status for study covariates were excluded from the analysis.</p><p>The statistical analysis was based on the national estimates,<xref rid="aogs14654-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> and a <italic toggle="yes">P</italic>&#8208;value &lt;0.05 was considered statistically significant (two&#8208;tailed).<xref rid="aogs14654-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> IBM SPSS Statistics (version 28.0, Armonk, NY, USA) was used for all analyses. This study followed the STROBE reporting guidelines to summarize the performance of the cohort study.<xref rid="aogs14654-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>
</p></sec><sec id="aogs14654-sec-0026"><label>2.7</label><title>Ethics statement</title><p>The National Inpatient Sample is publicly available on the Healthcare Cost and Utilization Project website for access by researchers (available on request at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.hcup-us.ahrq.gov" ext-link-type="uri">https://www.hcup&#8208;us.ahrq.gov</ext-link>), hence the current study was exempted from ethics approval (ethical committee exemption: HS&#8208;16&#8208;00481). Informed consent from patients was not required.</p></sec></sec><sec sec-type="results" id="aogs14654-sec-0015"><label>3</label><title>RESULTS</title><sec id="aogs14654-sec-0016"><label>3.1</label><title>Cohort statistics</title><p>Study selection schema is shown in Figure&#160;<xref rid="aogs14654-fig-0001" ref-type="fig">1</xref>. During the study period, 1605 pregnant patients had a diagnosis of breast cancer, 1190 pregnant patients had a diagnosis of leukemia, 1120 pregnant patients had a diagnosis of lymphoma, 715 pregnant patients had a diagnosis of thyroid cancer, 670 pregnant patients had a diagnosis of cervical cancer, and 400 pregnant patients had a diagnosis of melanoma, respectively. A total of 14&#8201;265&#8201;319 pregnant patients did not have any diagnosis of malignancy. All these patients were alive at hospital discharge and did not undergo hysterectomy during admission.</p><fig position="float" fig-type="FIGURE" id="aogs14654-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Study schema. CD, cesarean delivery; NIS, National Inpatient Sample; unk, unknown; VD, vaginal delivery.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="AOGS-103-695-g002.jpg"/></fig></sec><sec id="aogs14654-sec-0017"><label>3.2</label><title>Clinical demographics</title><p>Patient characteristics per exposure group are shown in Table&#160;<xref rid="aogs14654-tbl-0002" ref-type="table">2</xref>. Pregnant patients with malignancy were overall older than those without malignancy: the median ages at delivery were 34, 30, 31, 31, 31, 32 and 29 for breast cancer, leukemia, lymphoma, thyroid cancer, cervical cancer, melanoma and non&#8208;malignancy groups, respectively (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001). Pregnant patients with breast cancer had the highest rate of advanced maternal age at delivery (&#8805;35&#8201;years, 49.5%).</p><table-wrap position="float" id="aogs14654-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Clinical and obstetric characteristics.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Characteristic</th><th align="left" valign="bottom" rowspan="1" colspan="1">No malig</th><th align="left" valign="bottom" rowspan="1" colspan="1">Breast</th><th align="left" valign="bottom" rowspan="1" colspan="1">Leukemia</th><th align="left" valign="bottom" rowspan="1" colspan="1">Lymphoma</th><th align="left" valign="bottom" rowspan="1" colspan="1">Thyroid</th><th align="left" valign="bottom" rowspan="1" colspan="1">Cervical</th><th align="left" valign="bottom" rowspan="1" colspan="1">Melanoma</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>&#8208;value</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>
</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">14&#8201;265&#8201;319</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1605</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1190</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1120</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">715</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">425</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">400</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age, years</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">29 (25&#8211;33)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">34 (31&#8211;37)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">30 (26&#8211;34)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">31 (26&#8211;35)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">31 (27&#8211;36)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">31 (29&#8211;33)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">32 (30&#8211;35)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&lt;25</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3&#8201;409&#8201;604 (23.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">35 (2.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">250 (21)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">180 (16.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">90 (12.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">30 (7.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">20 (5.0)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">25&#8211;29</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4&#8201;111&#8201;678 (28.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">210 (13.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">330 (27.7)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">340 (30.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">160 (22.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">115 (27.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">75 (18.8)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">30&#8211;34</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4&#8201;124&#8201;498 (28.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">565 (35.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">360 (30.3)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">310 (27.7)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">245 (34.3)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">200 (47.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">175 (43.8)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#8805;35</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">2&#8201;619&#8201;539 (18.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">795 (49.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">250 (21.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">290 (25.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">220 (30.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">80 (18.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">130 (32.5)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Year</td><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">2017</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3&#8201;685&#8201;341 (25.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">365 (22.7)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">265 (22.3)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">305 (27.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">240 (33.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">100 (23.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">65 (16.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">2018</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3&#8201;613&#8201;219 (25.3)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">465 (29.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">300 (25.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">215 (19.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">180 (25.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">115 (27.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">115 (28.7)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">2019</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3&#8201;550&#8201;774 (24.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">385 (24.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">210 (17.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">310 (27.7)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">145 (20.3)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">115 (27.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">125 (31.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">2020</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3&#8201;415&#8201;985 (23.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">390 (24.3)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">415 (34.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">290 (25.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">150 (21.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">95 (22.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">95 (23.8)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Race/ethnicity</td><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">White</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">7&#8201;214&#8201;031 (50.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">855 (53.3)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">670 (56.3)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">670 (59.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">410 (57.3)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">265 (62.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">370 (92.5)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Black</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">2&#8201;077&#8201;040 (14.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">290 (18.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">150 (12.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">180 (16.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">35 (4.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">50 (11.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Hispanic</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">2&#8201;877&#8201;634 (20.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">210 (13.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">265 (22.3)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">160 (14.3)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">165 (23.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">70 (16.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Other</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1&#8201;581&#8201;329 (11.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">190 (11.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">70 (5.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">75 (6.7)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">80 (11.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">20 (4.7)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Unknown</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">515&#8201;284 (3.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">60 (3.7)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">35 (2.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">35 (3.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">25 (3.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">20 (4.7)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Primary payer</td><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Medicaid</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">6&#8201;019&#8201;933 (42.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">450 (28.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">440 (37.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">395 (35.3)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">230 (32.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">215 (50.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">80 (20.0)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Private</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">7&#8201;376&#8201;846 (51.7)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1010 (62.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">650 (54.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">665 (59.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">440 (61.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">185 (43.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">290 (72.5)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Other</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">851&#8201;325 (6.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">135 (8.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">95 (8.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">60 (5.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">45 (6.3)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">25 (5.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">30 (7.5)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Unknown</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">17&#8201;215 (0.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Obesity</td><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">12&#8201;545&#8201;885 (87.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1420 (88.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">980 (82.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">925 (92.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">590 (82.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">355 (83.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">325 (81.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1&#8201;719&#8201;435 (12.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">185 (11.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">210 (17.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">195 (17.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">125 (17.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">70 (16.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">75 (18.8)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tobacco use</td><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">13&#8201;531&#8201;315 (94.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1540 (96.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1140 (95.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1085 (96.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">680 (95.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">375 (88.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">360 (90.0)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">734&#8201;005 (5.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">65 (4.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">50 (4.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">35 (3.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">35 (4.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">50 (11.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">40 (10.0)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Uterine myoma</td><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">14&#8201;057&#8201;324 (98.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1555 (96.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1160 (97.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1095 (97.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">690 (96.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">415 (97.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">390 (97.5)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">207&#8201;995 (1.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">50 (3.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">30 (2.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">25 (2.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">25 (3.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hypertensive disorder</td><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">None</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">12&#8201;095&#8201;265 (84.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1400 (87.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">905 (76.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">915 (81.7)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">595 (83.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">340 (80.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">320 (80.0)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Pregestational</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">311&#8201;065 (2.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">25 (1.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">45 (3.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">40 (3.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">20 (2.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">15 (3.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">30 (7.5)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Gestational</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">828&#8201;840 (5.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">85 (5.3)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">110 (9.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">45 (4.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">60 (8.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">40 (9.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">20 (5.0)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Preeclampsia</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">933&#8201;385 (6.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">90 (5.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">105 (8.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">105 (9.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">40 (5.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">30 (7.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">30 (7.5)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">NOS</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">96&#8201;765 (0.7)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">25 (2.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">15 (1.3)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diabetes mellitus</td><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">None</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">12&#8201;915&#8201;935 (90.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1440 (89.7)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1055 (88.7)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">965 (86.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">600 (83.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">380 (89.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">360 (90.0)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Pregestational</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">161&#8201;320 (1.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">20 (1.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">15 (1.3)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">20 (1.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">30 (4.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Gestational</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1&#8201;169&#8201;365 (8.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">145 (9.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">105 (8.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">135 (12.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">85 (11.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">35 (8.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">30 (7.5)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">NOS</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">18&#8201;700 (0.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">15 (1.3)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Multifetal gestation</td><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="." valign="top" rowspan="1" colspan="1">0.014</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">14&#8201;012&#8201;619 (98.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1575 (98.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1170 (98.3)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1095 (97.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">715 (100)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">420 (98.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">395 (98.8)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">252&#8201;700 (1.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">30 (1.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">20 (1.7)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">25 (2.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fetal growth restriction</td><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">13&#8201;737&#8201;669 (96.3)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1495 (93.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1145 (96.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1050 (93.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">705 (98.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">400 (94.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">395 (98.8)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">527&#8201;650 (3.7)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">110 (6.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">45 (3.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">70 (6.3)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">25 (5.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fetal demise</td><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">14&#8201;152&#8201;939 (99.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1585 (98.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1165 (97.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1100 (98.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">710 (99.3)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">420 (98.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">390 (97.5)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">112&#8201;380 (0.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">20 (1.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">25 (2.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">20 (1.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Chorioamnionitis</td><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">13&#8201;929&#8201;999 (97.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1585 (98.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1165 (97.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1110 (99.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">710 (99.3)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">420 (98.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">390 (97.5)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">335&#8201;320 (2.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">20 (1.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">25 (2.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gestational age (w)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#8805;37</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">12&#8201;648&#8201;945 (88.7)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">910 (56.7)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">910 (76.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">785 (70.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">605 (84.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">250 (58.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">320 (80.0)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">34&#8211;36</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">990&#8201;355 (6.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">500 (31.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">120 (10.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">215 (19.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">60 (8.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">95 (22.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">50 (12.5)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&lt;34</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">443&#8201;095 (3.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">155 (9.7)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">120 (10.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">85 (7.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">40 (5.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">80 (18.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">30 (7.5)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Unknown</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">182&#8201;925 (1.3)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">40 (2.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">40 (3.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">35 (3.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hospital setting</td><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Rural</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1&#8201;281&#8201;338 (9.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">55 (3.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">30 (2.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">50 (4.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">35 (4.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">25 (6.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Urban non&#8208;teaching</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">2&#8201;694&#8201;336 (18.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">160 (10.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">155 (13.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">140 (12.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">130 (18.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">60 (14.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">75 (18.8)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Urban teaching</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">10&#8201;289&#8201;646 (72.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1390 (86.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1005 (84.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">930 (83.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">550 (76.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">355 (83.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">300 (75.0)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hospital region</td><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Northeast</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">2&#8201;274&#8201;859 (15.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">300 (18.7)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">205 (17.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">285 (25.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">110 (15.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">95 (22.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">55 (13.8)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Midwest</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3&#8201;006&#8201;463 (21.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">375 (23.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">280 (23.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">285 (25.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">160 (22.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">90 (21.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">95 (23.8)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">South</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">5&#8201;619&#8201;962 (39.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">560 (34.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">390 (32.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">345 (30.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">260 (36.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">130 (30.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">165 (41.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">West</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3&#8201;364&#8201;035 (23.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">370 (23.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">315 (26.5)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">205 (18.3)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">185 (25.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">110 (25.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">85 (21.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Delivery route</td><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Vaginal</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">9&#8201;676&#8201;741 (67.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1050 (65.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">680 (57.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">650 (58.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">465 (65.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">150 (35.3)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">255 (63.7)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Cesarean</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4&#8201;588&#8201;578 (32.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">555 (34.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">510 (42.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">470 (42.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">250 (35.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">275 (64.7)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">145 (36.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Severe maternal morbidity</td><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1"/><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">14&#8201;031&#8201;089 (98.4)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1540 (96.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1070 (89.9)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1095 (97.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">695 (97.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">390 (91.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">375 (93.8)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">234&#8201;230 (1.6)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">65 (4.0)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">120 (10.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">25 (2.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">20 (2.8)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">35 (8.2)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">25 (6.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot id="aogs14654-ntgp-0001"><fn id="aogs14654-note-0001"><p>
<italic toggle="yes">Note</italic>: Median (IQR) or percentage per column is shown. Kruskal&#8211;Wallis <italic toggle="yes">H&#8208;</italic>test or Pearson chi&#8208;square test for <italic toggle="yes">P</italic>&#8208;values.</p></fn><fn id="aogs14654-note-0002"><p>Abbreviations: breast, breast cancer; cervical, cervical cancer; no malig, no malignancy; NOS, not otherwise specified; thyroid, thyroid cancer.</p></fn><fn id="aogs14654-note-0003"><label>
<sup>a</sup>
</label><p>Small number suppressed per the HCUP guidelines.</p></fn></table-wrap-foot></table-wrap><p>Pregnant patients with melanoma were more likely to be White individuals (92.5% vs 50.6%&#8211;59.8%), whereas those with breast cancer were more likely to be black individuals (18.1% vs 4.9%&#8211;16.1%; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001). Obesity rates in pregnant patients with malignancy were overall higher compared with those without malignancy, except for breast cancer (16.5%&#8211;18.8% vs 12.1%; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001). Tobacco use rates among pregnant patients with cervical cancer and melanoma were higher compared with other groups (10.0%&#8211;11.8% vs 3.1%&#8211;5.1%; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001).</p></sec><sec id="aogs14654-sec-0018"><label>3.3</label><title>Pregnancy characteristics</title><p>The results are displayed in Table&#160;<xref rid="aogs14654-tbl-0002" ref-type="table">2</xref>. The hypertensive disorder rate exceeded 20% in pregnant patients with lymphoma, leukemia, cervical cancer and melanoma (28.3%, 23.9%, 20.0% and 20.0%, respectively, compared with 15.2% in the non&#8208;malignancy group; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001). Specifically, the pregestational hypertension rate was high in the melanoma group (7.5% vs 1.6%&#8211;3.6%); the gestational hypertension rate was high in the thyroid cancer, cervical, cancer and leukemia groups (8.4%&#8211;9.4% vs 5.0%&#8211;5.8%); and rate of preeclampsia was highest in the lymphoma group (9.4%).</p><p>Pregnant patients in the thyroid cancer group had the highest rate of pregestational diabetes (4.2% vs 1.1%&#8211;1.8%); gestational diabetes rates in the thyroid cancer and lymphoma groups were higher than in other groups (11.9%&#8211;12.1% vs 7.5%&#8211;9.0%; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001). Intrauterine fetal growth restriction rates in pregnant patients with breast cancer, lymphoma and cervical cancer were higher than in those without malignancy (5.9%&#8211;6.9% vs 3.7%; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001). Intrauterine fetal demise rates in pregnant patients with leukemia and lymphoma were clinically meaningfully higher compared with those without malignancy (1.8%&#8211;2.1% vs 0.8%; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001).</p></sec><sec id="aogs14654-sec-0019"><label>3.4</label><title>Delivery characteristics</title><p>Information on delivery data is shown in Table&#160;<xref rid="aogs14654-tbl-0002" ref-type="table">2</xref>. Preterm delivery rates in pregnant patients with cervical cancer and breast cancer were disproportionally high compared with other groups (40.9%&#8211;41.2% vs 10%&#8211;26.8%; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001). Specifically, pregnant patients with breast cancer had higher rates of late preterm delivery at 34&#8211;36&#8201;weeks&#8217; gestation (31.2% vs 6.9%&#8211;22.4%), whereas those with cervical cancer had higher rates of preterm delivery before 34&#8201;weeks&#8217; gestation (18.8% vs 3.1%&#8211;10.1%).</p><p>Nearly two&#8208;thirds of pregnant patients with cervical cancer underwent cesarean delivery, far higher higher than among the other exposure groups (64.7% vs 32.2%&#8211;42.9%: <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001). Severe maternal morbidity rates in pregnant patients with malignancy were overall higher compared with those without malignancy (2.2%&#8211;10.1% vs 1.6%; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001); this was particularly high in leukemia and cervical cancer (10.1% and 8.2%, respectively).</p></sec><sec id="aogs14654-sec-0020"><label>3.5</label><title>Contraception use/surgical sterilization</title><p>LARC and surgical sterilization choices per malignancy type at cohort level are shown in Table&#160;<xref rid="aogs14654-tbl-0003" ref-type="table">3</xref>. Among the non&#8208;malignancy group, the utilization of bilateral salpingectomy, BTL, IUD and subdermal implant at delivery were 50.8, 10.1, 5.6 and 3.5 per 1000 deliveries, respectively. Assessments of patient age, race and delivery factors are shown in Tables&#160;<xref rid="aogs14654-tbl-0004" ref-type="table">4</xref>, <xref rid="aogs14654-tbl-0005" ref-type="table">5</xref>, <xref rid="aogs14654-tbl-0006" ref-type="table">6</xref>.</p><table-wrap position="float" id="aogs14654-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Contraception and sterilization selection (whole cohort).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1"/><th colspan="4" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1">Permanent surgical sterilization</th><th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Long&#8208;acting reversible contraception</th></tr><tr style="border-bottom:solid 1px #000000"><th colspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1">Salpingectomy</th><th colspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1">BTL</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">IUD</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Subdermal implant</th></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Characteristics</th><th align="left" valign="bottom" rowspan="1" colspan="1">Rate<xref rid="aogs14654-note-0006" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">aOR (95% CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Rate<xref rid="aogs14654-note-0006" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">aOR (95% CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Rate<xref rid="aogs14654-note-0006" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">aOR (95% CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Rate<xref rid="aogs14654-note-0006" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">aOR (95% CI)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">No malignancy</td><td align="char" char="." valign="top" rowspan="1" colspan="1">50.8</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (reference)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">10.1</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (reference)</td><td align="left" valign="top" rowspan="1" colspan="1">5.6</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (reference)</td><td align="left" valign="top" rowspan="1" colspan="1">3.5</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (reference)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Breast cancer</td><td align="char" char="." valign="top" rowspan="1" colspan="1">137.1</td><td align="left" valign="top" rowspan="1" colspan="1">2.30 (1.96&#8211;2.70)<xref rid="aogs14654-note-0008" ref-type="table-fn">*</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0007" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.57 (0.30&#8211;1.07)</td><td align="left" valign="top" rowspan="1" colspan="1">9.3</td><td align="left" valign="top" rowspan="1" colspan="1">1.91 (1.14&#8211;3.19)<xref rid="aogs14654-note-0008" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Leukemia</td><td align="char" char="." valign="top" rowspan="1" colspan="1">63.0</td><td align="left" valign="top" rowspan="1" colspan="1">0.99 (0.77&#8211;1.27)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">12.6</td><td align="left" valign="top" rowspan="1" colspan="1">1.16 (0.69&#8211;1.95)</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0007" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.58 (0.24&#8211;1.40)</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0007" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">2.22 (1.19&#8211;4.17)<xref rid="aogs14654-note-0008" ref-type="table-fn">*</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lymphoma</td><td align="char" char="." valign="top" rowspan="1" colspan="1">107.1</td><td align="left" valign="top" rowspan="1" colspan="1">1.93 (1.57&#8211;2.38)<xref rid="aogs14654-note-0008" ref-type="table-fn">*</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">17.9</td><td align="left" valign="top" rowspan="1" colspan="1">1.76 (1.11&#8211;2.77)<xref rid="aogs14654-note-0008" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0007" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">1.51 (0.81&#8211;2.83)</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0007" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">1.55 (0.64&#8211;3.74)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Thyroid cancer</td><td align="char" char="." valign="top" rowspan="1" colspan="1">69.9</td><td align="left" valign="top" rowspan="1" colspan="1">1.11 (0.81&#8211;1.53)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">28.0</td><td align="left" valign="top" rowspan="1" colspan="1">2.21 (1.38&#8211;3.52)<xref rid="aogs14654-note-0008" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0007" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">1.39 (0.58&#8211;3.38)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cervical cancer</td><td align="char" char="." valign="top" rowspan="1" colspan="1">176.5</td><td align="left" valign="top" rowspan="1" colspan="1">2.08 (1.59&#8211;2.73)<xref rid="aogs14654-note-0008" ref-type="table-fn">*</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0007" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.81 (0.33&#8211;1.98)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Melanoma</td><td align="char" char="." valign="top" rowspan="1" colspan="1">62.5</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (0.65&#8211;1.53)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0007" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">1.09 (0.44&#8211;2.68)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot id="aogs14654-ntgp-0002"><fn id="aogs14654-note-0004"><p>
<italic toggle="yes">Note</italic>: A multinomial regression model for analysis. The exposure&#8211;outcome association was adjusted for clinical, pregnancy and delivery characteristics as shown in Table&#160;<xref rid="aogs14654-tbl-0002" ref-type="table">2</xref>. Age was examined as a continuous variable. Similar associations were demonstrated when cases with missing information in any of study covariates were excluded or when age was examined as a categorical variable (Table&#160;<xref rid="aogs14654-supitem-0001" ref-type="supplementary-material">S1</xref>).</p></fn><fn id="aogs14654-note-0005"><p>Abbreviations: aOR, adjusted odds ratio; BTL, bilateral salpingectomy; CI, confidence interval; IUD, intrauterine device.</p></fn><fn id="aogs14654-note-0006"><label>
<sup>a</sup>
</label><p>Per 1000 deliveries.</p></fn><fn id="aogs14654-note-0007"><label>
<sup>b</sup>
</label><p>Small number suppressed per the HCUP guidelines.</p></fn><fn id="aogs14654-note-0008"><label>*</label><p>
<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="aogs14654-tbl-0004" content-type="TABLE" orientation="portrait"><label>TABLE 4</label><caption><p>Assessment of patient age.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1"/><th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Permanent surgical sterilization</th><th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Long&#8208;acting reversible contraception</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Salpingectomy</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">BTL</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">IUD</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Subdermal implant</th></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Characteristics</th><th align="left" valign="bottom" rowspan="1" colspan="1">Rate<xref rid="aogs14654-note-0011" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">aOR (95%&#8201;CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Rate<xref rid="aogs14654-note-0011" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">aOR (95% CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Rate<xref rid="aogs14654-note-0011" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">aOR (95%&#8201;CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Rate<xref rid="aogs14654-note-0011" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">aOR (95%&#8201;CI)</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="9" valign="top" rowspan="1">Age&#8201;&#8805;30&#8201;years</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No malignancy</td><td align="left" valign="top" rowspan="1" colspan="1">74.1</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (reference)</td><td align="left" valign="top" rowspan="1" colspan="1">13.9</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (reference)</td><td align="left" valign="top" rowspan="1" colspan="1">5.0</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (reference)</td><td align="left" valign="top" rowspan="1" colspan="1">2.1</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (reference)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Breast cancer</td><td align="left" valign="top" rowspan="1" colspan="1">143.4</td><td align="left" valign="top" rowspan="1" colspan="1">2.32 (1.96&#8211;2.76)<xref rid="aogs14654-note-0013" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0012" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.66 (0.35&#8211;1.24)</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0012" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">1.76 (0.94&#8211;3.28)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Leukemia</td><td align="left" valign="top" rowspan="1" colspan="1">90.2</td><td align="left" valign="top" rowspan="1" colspan="1">1.02 (0.76&#8211;1.36)</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0012" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">1.06 (0.56&#8211;2.01)</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0012" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">1.20 (0.49&#8211;2.93)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Lymphoma</td><td align="left" valign="top" rowspan="1" colspan="1">133.3</td><td align="left" valign="top" rowspan="1" colspan="1">1.70 (1.31&#8211;2.21)<xref rid="aogs14654-note-0013" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">25.0</td><td align="left" valign="top" rowspan="1" colspan="1">1.78 (1.04&#8211;3.03)<xref rid="aogs14654-note-0013" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Thyroid cancer</td><td align="left" valign="top" rowspan="1" colspan="1">86.0</td><td align="left" valign="top" rowspan="1" colspan="1">1.18 (0.82&#8211;1.68)</td><td align="left" valign="top" rowspan="1" colspan="1">43.0</td><td align="left" valign="top" rowspan="1" colspan="1">3.02 (1.87&#8211;4.87)<xref rid="aogs14654-note-0013" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0012" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">2.13 (0.87&#8211;5.19)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Cervical cancer</td><td align="left" valign="top" rowspan="1" colspan="1">196.4</td><td align="left" valign="top" rowspan="1" colspan="1">1.78 (1.30&#8211;2.43)<xref rid="aogs14654-note-0013" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0012" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.98 (0.40&#8211;2.40)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Melanoma</td><td align="left" valign="top" rowspan="1" colspan="1">65.6</td><td align="left" valign="top" rowspan="1" colspan="1">0.95 (0.59&#8211;1.54)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="9" valign="top" rowspan="1">Age&#8201;&lt;30&#8201;years</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No malignancy</td><td align="left" valign="top" rowspan="1" colspan="1">29.9</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (reference)</td><td align="left" valign="top" rowspan="1" colspan="1">6.8</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (reference)</td><td align="left" valign="top" rowspan="1" colspan="1">6.1</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (reference)</td><td align="left" valign="top" rowspan="1" colspan="1">4.8</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (reference)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Breast cancer</td><td align="left" valign="top" rowspan="1" colspan="1">102.0</td><td align="left" valign="top" rowspan="1" colspan="1">3.01 (1.92&#8211;4.70)<xref rid="aogs14654-note-0013" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">20.4</td><td align="left" valign="top" rowspan="1" colspan="1">2.77 (1.11&#8211;6.95)<xref rid="aogs14654-note-0013" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Leukemia</td><td align="left" valign="top" rowspan="1" colspan="1">34.5</td><td align="left" valign="top" rowspan="1" colspan="1">0.95 (0.60&#8211;1.52)</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0012" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">1.46 (0.60&#8211;3.56)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0012" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">3.34 (1.77&#8211;6.29)<xref rid="aogs14654-note-0013" ref-type="table-fn">*</xref>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Lymphoma</td><td align="left" valign="top" rowspan="1" colspan="1">76.9</td><td align="left" valign="top" rowspan="1" colspan="1">2.08 (1.47&#8211;2.95)<xref rid="aogs14654-note-0013" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0012" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">1.34 (0.55&#8211;3.27)</td><td align="left" valign="top" rowspan="1" colspan="1">19.2</td><td align="left" valign="top" rowspan="1" colspan="1">3.24 (1.72&#8211;6.09)<xref rid="aogs14654-note-0013" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0012" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">2.49 (1.03&#8211;6.06)<xref rid="aogs14654-note-0013" ref-type="table-fn">*</xref>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Thyroid cancer</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0012" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">1.08 (0.56&#8211;2.10)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Cervical cancer</td><td align="left" valign="top" rowspan="1" colspan="1">137.9</td><td align="left" valign="top" rowspan="1" colspan="1">2.26 (1.34&#8211;3.82)<xref rid="aogs14654-note-0013" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Melanoma</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0012" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (0.39&#8211;2.56)</td><td align="left" valign="top" rowspan="1" colspan="1">52.6</td><td align="left" valign="top" rowspan="1" colspan="1">5.36 (2.07&#8211;13.87)<xref rid="aogs14654-note-0013" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot id="aogs14654-ntgp-0003"><fn id="aogs14654-note-0009"><p>
<italic toggle="yes">Note</italic>: A multinomial regression model for analysis. Adjusting model followed the whole cohort as shown in Table&#160;<xref rid="aogs14654-tbl-0003" ref-type="table">3</xref>. Adjusted odds ratio and corresponding 95% confidence interval for the contraception and sterilization are shown for each malignancy type. The non&#8208;malignancy group served as reference group.</p></fn><fn id="aogs14654-note-0010"><p>Abbreviations: aOR, adjusted odds ratio; BTL, bilateral salpingectomy; CI, confidence interval; IUD, intrauterine device.</p></fn><fn id="aogs14654-note-0011"><label>
<sup>a</sup>
</label><p>Per 1000 deliveries.</p></fn><fn id="aogs14654-note-0012"><label>
<sup>b</sup>
</label><p>Small number suppressed per the HCUP guidelines.</p></fn><fn id="aogs14654-note-0013"><label>*</label><p>
<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="aogs14654-tbl-0005" content-type="TABLE" orientation="portrait"><label>TABLE 5</label><caption><p>Assessment of race and ethnicity.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1"/><th colspan="4" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1">Permanent surgical sterilization</th><th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Long&#8208;acting reversible contraception</th></tr><tr style="border-bottom:solid 1px #000000"><th colspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1">Salpingectomy</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">BTL</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">IUD</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Subdermal implant</th></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Characteristics</th><th align="left" valign="bottom" rowspan="1" colspan="1">Rate<xref rid="aogs14654-note-0016" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">aOR (95% CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Rate<xref rid="aogs14654-note-0016" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">aOR (95% CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Rate<xref rid="aogs14654-note-0016" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">aOR (95% CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Rate<xref rid="aogs14654-note-0016" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">aOR (95% CI)</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="9" valign="top" rowspan="1">White individuals</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No malignancy</td><td align="char" char="." valign="top" rowspan="1" colspan="1">48.3</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (reference)</td><td align="left" valign="top" rowspan="1" colspan="1">9.7</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (reference)</td><td align="left" valign="top" rowspan="1" colspan="1">3.3</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (reference)</td><td align="left" valign="top" rowspan="1" colspan="1">1.4</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (reference)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Breast cancer</td><td align="char" char="." valign="top" rowspan="1" colspan="1">134.5</td><td align="left" valign="top" rowspan="1" colspan="1">3.07 (2.46&#8211;3.82)<xref rid="aogs14654-note-0018" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0017" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">2.09 (0.87&#8211;5.06)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Leukemia</td><td align="char" char="." valign="top" rowspan="1" colspan="1">89.6</td><td align="left" valign="top" rowspan="1" colspan="1">1.43 (1.07&#8211;1.90)<xref rid="aogs14654-note-0018" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0017" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.78 (0.32&#8211;1.89)</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0017" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">1.80 (0.74&#8211;4.35)</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0017" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">5.47 (2.25&#8211;13.30)<xref rid="aogs14654-note-0018" ref-type="table-fn">*</xref>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Lymphoma</td><td align="char" char="." valign="top" rowspan="1" colspan="1">104.5</td><td align="left" valign="top" rowspan="1" colspan="1">2.00 (1.52&#8211;2.62)<xref rid="aogs14654-note-0018" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">14.9</td><td align="left" valign="top" rowspan="1" colspan="1">1.62 (0.86&#8211;3.07)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Thyroid cancer</td><td align="char" char="." valign="top" rowspan="1" colspan="1">73.2</td><td align="left" valign="top" rowspan="1" colspan="1">1.26 (0.85&#8211;1.89)</td><td align="left" valign="top" rowspan="1" colspan="1">36.6</td><td align="left" valign="top" rowspan="1" colspan="1">3.03 (1.75&#8211;5.24)<xref rid="aogs14654-note-0018" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Cervical cancer</td><td align="char" char="." valign="top" rowspan="1" colspan="1">132.1</td><td align="left" valign="top" rowspan="1" colspan="1">1.40 (0.96&#8211;2.06)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Melanoma</td><td align="char" char="." valign="top" rowspan="1" colspan="1">67.6</td><td align="left" valign="top" rowspan="1" colspan="1">1.10 (0.72&#8211;1.70)</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0017" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">1.19 (0.48&#8211;2.93)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="9" valign="top" rowspan="1">Non&#8208;White individuals</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No malignancy</td><td align="char" char="." valign="top" rowspan="1" colspan="1">54.3</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (reference)</td><td align="left" valign="top" rowspan="1" colspan="1">10.7</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (reference)</td><td align="left" valign="top" rowspan="1" colspan="1">8.3</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (reference)</td><td align="left" valign="top" rowspan="1" colspan="1">5.8</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (reference)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Breast cancer</td><td align="char" char="." valign="top" rowspan="1" colspan="1">137.7</td><td align="left" valign="top" rowspan="1" colspan="1">1.72 (1.34&#8211;2.19)<xref rid="aogs14654-note-0018" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0017" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.91 (0.48&#8211;1.72)</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0017" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">1.85 (0.98&#8211;3.49)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Leukemia</td><td align="char" char="." valign="top" rowspan="1" colspan="1">30.9</td><td align="left" valign="top" rowspan="1" colspan="1">0.53 (0.31&#8211;0.90)<xref rid="aogs14654-note-0018" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">20.6</td><td align="left" valign="top" rowspan="1" colspan="1">1.94 (1.02&#8211;3.72)<xref rid="aogs14654-note-0018" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0017" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">1.43 (0.59&#8211;3.47)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Lymphoma</td><td align="char" char="." valign="top" rowspan="1" colspan="1">120.5</td><td align="left" valign="top" rowspan="1" colspan="1">2.01 (1.45&#8211;2.80)<xref rid="aogs14654-note-0018" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0017" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">2.16 (1.12&#8211;4.16)<xref rid="aogs14654-note-0018" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0017" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">2.56 (1.36&#8211;4.83)<xref rid="aogs14654-note-0018" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0017" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">2.22 (0.92&#8211;5.40)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Thyroid cancer</td><td align="char" char="." valign="top" rowspan="1" colspan="1">71.4</td><td align="left" valign="top" rowspan="1" colspan="1">0.91 (0.55&#8211;1.52)</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0017" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">1.16 (0.46&#8211;2.92)</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0017" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">2.27 (0.93&#8211;5.56)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Cervical cancer</td><td align="char" char="." valign="top" rowspan="1" colspan="1">285.7</td><td align="left" valign="top" rowspan="1" colspan="1">3.84 (2.57&#8211;5.73)<xref rid="aogs14654-note-0018" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0017" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">2.57 (1.02&#8211;6.48)<xref rid="aogs14654-note-0018" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Melanoma</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot id="aogs14654-ntgp-0004"><fn id="aogs14654-note-0014"><p>
<italic toggle="yes">Note</italic>: A multinomial regression model for analysis. Adjusting model followed the whole cohort as shown in Table&#160;<xref rid="aogs14654-tbl-0003" ref-type="table">3</xref>. Adjusted odds ratio and corresponding 95% confidence interval for the contraception and sterilization are shown for each malignancy type. The non&#8208;malignancy group served as reference group.</p></fn><fn id="aogs14654-note-0015"><p>Abbreviations: aOR, adjusted odds ratio; BTL, bilateral salpingectomy; CI, confidence interval; IUD, intrauterine device.</p></fn><fn id="aogs14654-note-0016"><label>
<sup>a</sup>
</label><p>Per 1000 deliveries.</p></fn><fn id="aogs14654-note-0017"><label>
<sup>b</sup>
</label><p>Small number suppressed per the HCUP guidelines.</p></fn><fn id="aogs14654-note-0018"><label>*</label><p>
<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="aogs14654-tbl-0006" content-type="TABLE" orientation="portrait"><label>TABLE 6</label><caption><p>Assessment of delivery route.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1"/><th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Permanent surgical sterilization</th><th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Long&#8208;acting reversible contraception</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Salpingectomy</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">BTL</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">IUD</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Subdermal implant</th></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Characteristics</th><th align="left" valign="bottom" rowspan="1" colspan="1">Rate<xref rid="aogs14654-note-0021" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">aOR (95% CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Rate<xref rid="aogs14654-note-0021" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">aOR (95% CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Rate<xref rid="aogs14654-note-0021" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">aOR (95% CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Rate<xref rid="aogs14654-note-0021" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">aOR (95% CI)</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="9" valign="top" rowspan="1">Vaginal delivery</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No malignancy</td><td align="left" valign="top" rowspan="1" colspan="1">13.2</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (reference)</td><td align="left" valign="top" rowspan="1" colspan="1">2.7</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (reference)</td><td align="left" valign="top" rowspan="1" colspan="1">4.8</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (reference)</td><td align="left" valign="top" rowspan="1" colspan="1">3.7</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (reference)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Breast cancer</td><td align="left" valign="top" rowspan="1" colspan="1">23.8</td><td align="left" valign="top" rowspan="1" colspan="1">1.38 (0.92&#8211;2.06)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">14.3</td><td align="left" valign="top" rowspan="1" colspan="1">3.43 (2.05&#8211;5.73)<xref rid="aogs14654-note-0023" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Leukemia</td><td align="left" valign="top" rowspan="1" colspan="1">22.1</td><td align="left" valign="top" rowspan="1" colspan="1">1.89 (1.13&#8211;3.18)<xref rid="aogs14654-note-0023" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0022" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">3.92 (1.62&#8211;9.48)<xref rid="aogs14654-note-0023" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0022" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">1.85 (0.76&#8211;4.49)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Lymphoma</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0022" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">1.29 (0.69&#8211;2.43)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0022" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">3.08 (1.64&#8211;5.77)<xref rid="aogs14654-note-0023" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Thyroid cancer</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0022" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.66 (0.27&#8211;1.61)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">10.8</td><td align="left" valign="top" rowspan="1" colspan="1">2.23 (0.92&#8211;5.43)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Cervical cancer</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Melanoma</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0022" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">3.19 (1.67&#8211;6.11)<xref rid="aogs14654-note-0023" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="9" valign="top" rowspan="1">Cesarean delivery</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No malignancy</td><td align="left" valign="top" rowspan="1" colspan="1">130.0</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (reference)</td><td align="left" valign="top" rowspan="1" colspan="1">25.8</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (reference)</td><td align="left" valign="top" rowspan="1" colspan="1">7.1</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (reference)</td><td align="left" valign="top" rowspan="1" colspan="1">3.0</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (reference)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Breast cancer</td><td align="left" valign="top" rowspan="1" colspan="1">351.4</td><td align="left" valign="top" rowspan="1" colspan="1">2.66 (2.22&#8211;3.20)<xref rid="aogs14654-note-0023" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0022" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.73 (0.39&#8211;1.37)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Leukemia</td><td align="left" valign="top" rowspan="1" colspan="1">117.6</td><td align="left" valign="top" rowspan="1" colspan="1">0.84 (0.64&#8211;1.11)</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0022" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.82 (0.43&#8211;1.54)</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0022" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">1.05 (0.43&#8211;2.57)</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0022" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">2.72 (1.11&#8211;6.65)<xref rid="aogs14654-note-0023" ref-type="table-fn">*</xref>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Lymphoma</td><td align="left" valign="top" rowspan="1" colspan="1">234.0</td><td align="left" valign="top" rowspan="1" colspan="1">2.07 (1.65&#8211;2.59)<xref rid="aogs14654-note-0023" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">42.6</td><td align="left" valign="top" rowspan="1" colspan="1">2.06 (1.30&#8211;3.27)<xref rid="aogs14654-note-0023" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0022" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">4.06 (1.66&#8211;9.94)<xref rid="aogs14654-note-0023" ref-type="table-fn">*</xref>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Thyroid cancer</td><td align="left" valign="top" rowspan="1" colspan="1">180.0</td><td align="left" valign="top" rowspan="1" colspan="1">1.24 (0.88&#8211;1.75)</td><td align="left" valign="top" rowspan="1" colspan="1">80.0</td><td align="left" valign="top" rowspan="1" colspan="1">2.73 (1.69&#8211;4.41)<xref rid="aogs14654-note-0023" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Cervical cancer</td><td align="left" valign="top" rowspan="1" colspan="1">272.7</td><td align="left" valign="top" rowspan="1" colspan="1">2.24 (1.70&#8211;2.96)<xref rid="aogs14654-note-0023" ref-type="table-fn">*</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0022" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.88 (0.36&#8211;2.15)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Melanoma</td><td align="left" valign="top" rowspan="1" colspan="1">103.4</td><td align="left" valign="top" rowspan="1" colspan="1">0.65 (0.38&#8211;1.12)</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="aogs14654-note-0022" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">1.17 (0.47&#8211;2.89)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot id="aogs14654-ntgp-0005"><fn id="aogs14654-note-0019"><p>
<italic toggle="yes">Note</italic>: Black, Hispanic, Asian and Native American were examined. A multinomial regression model for analysis. Adjusting model followed the whole cohort as shown in Table&#160;<xref rid="aogs14654-tbl-0003" ref-type="table">3</xref>. Adjusted odds ratio and corresponding 95% confidence interval for the contraception and sterilization are shown for each malignancy type. The non&#8208;malignancy group served as reference group.</p></fn><fn id="aogs14654-note-0020"><p>Abbreviations: aOR, adjusted&#8208;odds ratio; BTL, bilateral salpingectomy; CI, confidence interval; IUD, intrauterine device.</p></fn><fn id="aogs14654-note-0021"><label>
<sup>a</sup>
</label><p>Per 1000 deliveries.</p></fn><fn id="aogs14654-note-0022"><label>
<sup>b</sup>
</label><p>Small number suppressed per the HCUP guidelines.</p></fn><fn id="aogs14654-note-0023"><label>*</label><p>
<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05.</p></fn></table-wrap-foot></table-wrap><p>When compared with pregnant patients without malignancy, pregnant patients with breast cancer were more likely to proceed with bilateral salpingectomy (aOR 2.30, 95%&#8201;CI 1.96&#8211;2.70) or IUD (aOR 1.91, 95%&#8201;CI 1.14&#8211;3.19); none received the subdermal implant. The odds of proceeding with bilateral salpingectomy were particularly increased in white individuals (aOR 3.07, 95% CI 2.46&#8211;3.82), younger patients aged &lt;30&#8201;years (aOR 3.01, 95% CI 1.92&#8211;4.70) and those who had a cesarean delivery (aOR 2.66, 95% CI 2.22&#8211;3.20). The odds of choosing an IUD was increased in patients who had a vaginal delivery (aOR 3.43, 95% CI 2.05&#8211;5.73) and younger patients aged &lt;30&#8201;years (aOR 2.77, 95% CI 1.11&#8211;6.95).</p><p>Pregnant patients with leukemia were more likely to choose the subdermal implant (aOR 2.22, 95% CI 1.19&#8211;4.17). This increased odds of subdermal implant use was robust in white individuals (aOR 5.47, 95% CI 2.25&#8211;13.30), younger patients aged &lt;30&#8201;years (aOR 3.34, 95% CI 1.77&#8211;6.29) and those who had a cesarean delivery (aOR 2.72, 95% CI 1.11&#8211;6.65).</p><p>Pregnant patients with lymphoma were more likely to proceed with bilateral salpingectomy (aOR 1.93, 95% CI 1.57&#8211;2.38) and BTL (aOR 1.76, 95% CI 1.11&#8211;2.77) at cohort level. The increased odds of bilateral salpingectomy were overall consistent among these subgroups, except for vaginal delivery. Younger patients &lt;30&#8201;years old (aOR 3.24, 95% CI 1.72&#8211;6.09), patients who had vaginal deliveries (aOR 3.08, 95% CI 1.64&#8211;5.77), and non&#8208;white individuals (aOR 2.56, 95% CI 1.36&#8211;4.83) had increased odds of IUD use, whereas the odds of subdermal implant use was increased in patients who had cesarean delivery (aOR 4.06, 95% CI 1.66&#8211;9.94) and younger patients aged &lt;30&#8201;years (aOR 2.49, 95% CI 1.03&#8211;6.06).</p><p>Pregnant patients with thyroid cancer were more likely to proceed with BTL (aOR 2.21, 95% CI 1.38&#8211;3.52) and none received the subdermal implant. This increased utilization of BTL was more prominent in white individuals (aOR 3.03, 95% CI 1.75&#8211;5.24), older patients aged &#8805;30&#8201;years (aOR 3.02, 95% CI 1.87&#8211;4.87) and those who had a cesarean delivery (aOR 2.73, 95% CI 1.69&#8211;4.41).</p><p>No patients in the cervical cancer group selected an LARC (both subdermal implant and IUD) but they were more likely to proceed with bilateral salpingectomy (aOR 2.08, 95% CI 1.59&#8211;2.73). Specifically, non&#8208;white individuals (aOR 3.84, 95% CI 2.57&#8211;5.73), younger patients aged &lt;30&#8201;years (aOR 2.26, 95% CI 1.34&#8211;3.82) and those who had a cesarean delivery (aOR 2.24, 95% CI 1.70&#8211;2.96) had higher odds of proceeding with bilateral salpingectomy compared with cohort level (aOR &gt;2.08). Non&#8208;white individuals also had increased odds of proceeding with BTL (aOR 2.57, 95% CI 1.02&#8211;6.48).</p><p>None in the melanoma group chose LARC with subdermal implant or IUD; however, the odds of choosing BTL was increased in younger patients aged &lt;30&#8201;years in this population (aOR 5.36, 95% CI 2.07&#8211;13.87).</p></sec></sec><sec sec-type="discussion" id="aogs14654-sec-0021"><label>4</label><title>DISCUSSION</title><p>Key results of this analysis identified large variations in contraception and surgical sterilization selection across the six malignancy groups in this study. Overall, there appears to be a trend toward permanent surgical sterilization in a majority of malignancy types; and LARC, particularly the subdermal implant, was less favored in pregnant patients with solid tumors.</p><p>There is a high incidence of breast cancer among pregnancies complicated by malignancy.<xref rid="aogs14654-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> This poses a problem in contraceptive counseling given the hormonal dependency associated with breast cancer. Though treatment may eventually render patients amenorrheic, younger reproductive&#8208;age patients may have persistent fertility, requiring discussion of family planning options at the time of delivery.<xref rid="aogs14654-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>
</p><p>Our study found that patients with breast cancer were more likely to proceed with bilateral salpingectomy or IUD at the time of delivery, with the incidence of bilateral salpingectomy being notably higher in patients undergoing cesarean delivery. Few patients selected BTL and no patients selected the subdermal implant. The World Health Organization clearly states that hormonal contraception in breast cancer patients is contraindicated, which explains the absence of systemic hormonal therapy found in our study and the preference for surgical sterilization.</p><p>Although this study does not distinguish between copper and levonorgestrel IUDs, both are reasonable options in this population. Levonorgestrel IUDs may be placed in postpartum patients planning to undergo treatment with tamoxifen, and copper IUDs are established as an effective nonhormonal contraceptive option for all patients.</p><p>Treatment of leukemia involves systemic chemotherapy, radiation, bone marrow transplant or a combination of these methods. This can result in clinically significant levels of anemia and an increased need for menstrual suppression. In our study, pregnant patients with leukemia were more likely to choose the subdermal implant for postpartum contraception. This may be partially due to the incidence of amenorrhea conferred with the etonogestrel implant, most often quoted as 22.2%.<xref rid="aogs14654-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> The subdermal implant is also highly efficacious, with typical use conferring 99% success preventing pregnancy.<xref rid="aogs14654-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref> Notably, the White population with leukemia was more likely to proceed with bilateral salpingectomy compared with patients without malignancy, whereas non&#8208;White individuals were less likely to select bilateral salpingectomy. This may reflect differences in counseling among these populations.</p><p>In contrast to pregnant patients with leukemia, those with lymphoma were more likely to choose surgical sterilization than LARCs. Post hoc, these two malignancy groups had overall similar clinical, pregnancy and delivery characteristics, except for the increased rate of severe maternal morbidity in leukemia compared with lymphoma (10.1% vs 2.2%). This may in part explain the difference in the selection, but also warrants further investigation to validate our findings.</p><p>Pregnant patients with thyroid cancer were overall more likely to proceed with BTL, and none received the subdermal implant. No patients &lt;30&#8201;years were found to select BTL, indicating a desire for future fertility in the younger population. Limited studies have addressed the contraceptive options for postpartum patients with active thyroid cancer, so this study adds new information to the literature on contraceptive choices made by these patients. A general lack of concrete information on this topic for both patients and physicians may steer postpartum counseling toward surgical sterilization and away from the potential interactions of hormonal management with LARC.</p><p>No patients in the cervical cancer group selected LARCs. They were more likely to proceed with bilateral salpingectomy. All patients who selected bilateral salpingectomy had a cesarean delivery. The World Health Organization discourages initiation of IUDs, both levonorgestrel and copper, in women with active cervical cancer due to the risk of bleeding and infection,<xref rid="aogs14654-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> categorizing these as nonviable options for patients in the postpartum period and consistent with the decreased use of LARCs seen in this study. This was the only group studied where the majority of patients underwent cesarean section, which likely facilitated decisions to pursue permanent sterilization when considering the limited reproductive potential after cervical cancer treatment.</p><p>Melanoma in pregnancy is relatively well studied, as it is one of the most common cancers diagnosed in this population; however, there may be some component of delayed diagnosis because of the physiologic hyperpigmentation and dermatologic skin changes of pregnancy.<xref rid="aogs14654-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref> In our study, no patients selected LARCs. No association was observed for surgical sterilization. These findings may be due to a lack of adequate contraceptive counseling prior to delivery. Alternatively, these patients may be choosing methods not assessed in this study.</p><p>There are several limitations in this analysis. First, unmeasured confounders may possibly influence the observed exposure&#8211;outcome association. These included malignancy status (eg timing of cancer diagnosis [prior to or during pregnancy], active disease or remission, and stage of disease), treatment of malignancy (eg chemotherapy and surgery), and timing of diagnosis (prior to or during pregnancy).</p><p>Additionally, information regarding shared decision&#8208;making for contraception and surgical sterilization between patient and obstetrician, neonatal outcome, number of past deliveries, type of IUD (hormonal or non&#8208;hormonal) and long&#8208;term information (eg contraception use and sterilization after hospital discharge) were not available in the National Inpatient Sample; these unmeasured factors may possibly have confounded the analysis. Despite various analytic approaches, it is paramount to recognize that residual confounding effect of patient age on outcome measure was a major drawback in the study and careful interpretation is necessary.</p><p>Patient satisfaction, regrets and subsequent pregnancy were also not available in the dataset, but these are important measures for this type of study. The exposure and outcome measures were assigned based on the administrative codes alone, and the accuracy of data was not assessable without actual medical record review. This study examined the US population only, and generalizability in different regions was not assessed.</p></sec><sec sec-type="conclusions" id="aogs14654-sec-0022"><label>5</label><title>CONCLUSION</title><p>The results of this national&#8208;level analysis add important information to the literature. These findings suggest that malignancy during pregnancy is not a single disease entity and there are distinct differences in clinical, pregnancy and delivery characteristics that vary based on type of malignancy. The results also suggest that pregnant patients with malignancy and their providers are taking the various patient, pregnancy and disease factors into account in post&#8208;delivery family planning during pregnancy or at delivery. Given the lack of resources specific to pregnant patients with malignancy, developing clinical practice guidelines for postpartum contraception and sterilization counseling would be useful.</p></sec><sec id="aogs14654-sec-0023"><title>AUTHOR CONTRIBUTIONS</title><p>CAH generated the study concept, interpreted the results and drafted the article with KM. RSM accessed the data source, generated/cleaned the dataset, interpreted the results and revised the article. RSM and KM have full access and responsibility for the data. ARR and BBS contributed to the study discussion and intellectual inputs, performed literature review, interpreted the results, and edited the article. MK, JGO, RJP and LDR interpreted the results, supervised the study team, and revised the article. KM designed the study, initiated the collaborations, cleaned and analyzed the data, created the figures and tables, interpreted the results, and drafted and revised the article with others. The manuscript's corresponding author (KM) affirms that the manuscript is an honest, accurate and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained. The National Inpatient Sample was developed for the Healthcare Cost and Utilization Project sponsored by the Agency for Healthcare Research and Quality, and the program is the source of the de&#8208;identified data used; race/ethnicity was grouped by the program; and the program has not verified and is not responsible for the statistical validity of the data analysis or the conclusions derived by the study team.</p></sec><sec id="aogs14654-sec-0027"><title>FUNDING INFORMATION</title><p>Ensign Endowment for Gynecologic Cancer Research (KM).</p></sec><sec sec-type="COI-statement" id="aogs14654-sec-0028"><title>CONFLICT OF INTEREST STATEMENT</title><p>RJP: Consultant, Ferring. MK: consultant, CooperSurgical, KLS Martin. LDR: consultant, Cardiff Oncology, Nutcracker Therapeutics and AXDEV, and Steering Committee, Global Coalition of Adaptive Research. The other authors have stated explicitly that they have no conflicts of interest in connection with this article.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="aogs14654-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Table S1.</bold> Sensitivity analysis for age.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="AOGS-103-695-s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><sec sec-type="data-availability" id="aogs14654-sec-0025"><title>DATA AVAILABILITY STATEMENT</title><p>The data that support the findings of this study are openly available in Healthcare Cost and Utilization Project, Agency for Healthcare Research and Quality at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.hcup-us.ahrq.gov/nassoverview.jsp" ext-link-type="uri" specific-use="software is-supplemented-by">https://www.hcup&#8208;us.ahrq.gov/nassoverview.jsp</ext-link>.</p></sec><ref-list content-type="cited-references" id="aogs14654-bibl-0001"><title>REFERENCES</title><ref id="aogs14654-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="aogs14654-cit-0001"><string-name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname><given-names>KD</given-names></string-name>, <string-name name-style="western"><surname>Wagle</surname><given-names>NS</given-names></string-name>, <string-name name-style="western"><surname>Jemal</surname><given-names>A</given-names></string-name>. <article-title>Cancer statistics, 2023</article-title>. <source>CA Cancer J Clin</source>. <year>2023</year>;<volume>73</volume>:<fpage>17</fpage>&#8208;<lpage>48</lpage>.<pub-id pub-id-type="pmid">36633525</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21763</pub-id></mixed-citation></ref><ref id="aogs14654-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="aogs14654-cit-0002"><string-name name-style="western"><surname>Berndt</surname><given-names>VK</given-names></string-name>, <string-name name-style="western"><surname>Bell</surname><given-names>AV</given-names></string-name>. <article-title>&#8220;This is what the truth is&#8221;: provider&#8208;patient interactions serving as barriers to contraception</article-title>. <source>Health (London)</source>. <year>2021</year>;<volume>25</volume>:<fpage>613</fpage>&#8208;<lpage>629</lpage>.<pub-id pub-id-type="pmid">33124481</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1363459320969775</pub-id></mixed-citation></ref><ref id="aogs14654-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="aogs14654-cit-0003"><string-name name-style="western"><surname>Lambertini</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Massarotti</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Havas</surname><given-names>J</given-names></string-name>, et al. <article-title>Contraceptive use in premenopausal women with early breast cancer</article-title>. <source>JAMA Netw Open</source>. <year>2022</year>;<volume>5</volume>:<elocation-id>e2233137</elocation-id>.<pub-id pub-id-type="pmid">36149651</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2022.33137</pub-id><pub-id pub-id-type="pmcid">PMC9508662</pub-id></mixed-citation></ref><ref id="aogs14654-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="aogs14654-cit-0004"><string-name name-style="western"><surname>Curtis</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Tepper</surname><given-names>NK</given-names></string-name>, <string-name name-style="western"><surname>Jatlaoui</surname><given-names>TC</given-names></string-name>, et al. <article-title>U.S. medical eligibility criteria for contraceptive use, 2016</article-title>. <source>MMWR Recomm Rep</source>. <year>2016</year>;<volume>65</volume>:<fpage>1</fpage>&#8208;<lpage>103</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.rr6503a1</pub-id><pub-id pub-id-type="pmid">27467196</pub-id></mixed-citation></ref><ref id="aogs14654-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="aogs14654-cit-0005"><string-name name-style="western"><surname>Matsuo</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Klar</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Youssefzadeh</surname><given-names>AC</given-names></string-name>, et al. <article-title>Assessment of severe maternal morbidity and mortality in pregnancies complicated by cancer in the US</article-title>. <source>JAMA Oncol</source>. <year>2022</year>;<volume>8</volume>:<fpage>1213</fpage>&#8208;<lpage>1216</lpage>.<pub-id pub-id-type="pmid">35708707</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2022.1795</pub-id><pub-id pub-id-type="pmcid">PMC9204612</pub-id></mixed-citation></ref><ref id="aogs14654-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="aogs14654-cit-0006"><string-name name-style="western"><surname>Eibye</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kj&#230;r</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Mellemkj&#230;r</surname><given-names>L</given-names></string-name>. <article-title>Incidence of pregnancy&#8208;associated cancer in Denmark, 1977&#8208;2006</article-title>. <source>Obstet Gynecol</source>. <year>2013</year>;<volume>122</volume>:<fpage>608</fpage>&#8208;<lpage>617</lpage>.<pub-id pub-id-type="pmid">23921869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/AOG.0b013e3182a057a2</pub-id></mixed-citation></ref><ref id="aogs14654-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="aogs14654-cit-0007"><string-name name-style="western"><surname>Lee</surname><given-names>YY</given-names></string-name>, <string-name name-style="western"><surname>Roberts</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Dobbins</surname><given-names>T</given-names></string-name>, et al. <article-title>Incidence and outcomes of pregnancy&#8208;associated cancer in Australia, 1994&#8208;2008: a population&#8208;based linkage study</article-title>. <source>BJOG</source>. <year>2012</year>;<volume>119</volume>:<fpage>1572</fpage>&#8208;<lpage>1582</lpage>.<pub-id pub-id-type="pmid">22947229</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1471-0528.2012.03475.x</pub-id><pub-id pub-id-type="pmcid">PMC3533794</pub-id></mixed-citation></ref><ref id="aogs14654-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="aogs14654-cit-0008"><string-name name-style="western"><surname>Milbourne</surname><given-names>A</given-names></string-name>. <article-title>Management of pregnant patients with cancer</article-title>. <source>Oncology (Williston Park)</source>. <year>2016</year>;<volume>30</volume>:<fpage>448</fpage>&#8208;<lpage>450</lpage>.<pub-id pub-id-type="pmid">27188676</pub-id></mixed-citation></ref><ref id="aogs14654-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="aogs14654-cit-0009"><string-name name-style="western"><surname>Theriault</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Hahn</surname><given-names>K</given-names></string-name>. <article-title>Management of breast cancer in pregnancy</article-title>. <source>Curr Oncol Rep</source>. <year>2007</year>;<volume>9</volume>:<fpage>17</fpage>&#8208;<lpage>21</lpage>.<pub-id pub-id-type="pmid">17164043</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF02951421</pub-id></mixed-citation></ref><ref id="aogs14654-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="aogs14654-cit-0010"><string-name name-style="western"><surname>Sheyn</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Arora</surname><given-names>KS</given-names></string-name>. <article-title>Changes in rates of inpatient postpartum long&#8208;acting reversible contraception and sterilization in the USA, 2012&#8208;2016</article-title>. <source>Matern Child Health J</source>. <year>2021</year>;<volume>25</volume>:<fpage>1562</fpage>&#8208;<lpage>1573</lpage>.<pub-id pub-id-type="pmid">33970416</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10995-021-03152-0</pub-id><pub-id pub-id-type="pmcid">PMC8449803</pub-id></mixed-citation></ref><ref id="aogs14654-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="aogs14654-cit-0011"><string-name name-style="western"><surname>Stanback</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Steiner</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Dorflinger</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Solo</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Cates</surname><given-names>W</given-names><suffix>Jr</suffix></string-name>. <article-title>WHO tiered&#8208;effectiveness counseling is rights&#8208;based family planning</article-title>. <source>Glob Health Sci Pract</source>. <year>2015</year>;<volume>3</volume>:<fpage>352</fpage>&#8208;<lpage>357</lpage>.<pub-id pub-id-type="pmid">26374797</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.9745/GHSP-D-15-00096</pub-id><pub-id pub-id-type="pmcid">PMC4570010</pub-id></mixed-citation></ref><ref id="aogs14654-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="aogs14654-cit-0012"><string-name name-style="western"><surname>Dominick</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>McLean</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Whitcomb</surname><given-names>BW</given-names></string-name>, et al. <article-title>Contraceptive practices among female cancer survivors of reproductive age</article-title>. <source>Obstet Gynecol</source>. <year>2015</year>;<volume>126</volume>:<fpage>498</fpage>&#8208;<lpage>507</lpage>.<pub-id pub-id-type="pmid">26181090</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/AOG.0000000000000963</pub-id><pub-id pub-id-type="pmcid">PMC4545298</pub-id></mixed-citation></ref><ref id="aogs14654-bib-0013"><label>13</label><mixed-citation publication-type="miscellaneous" id="aogs14654-cit-0013"><collab collab-type="authors">Overview of the National (Nationwide) Inpatient Sample (NIS)</collab>
. <article-title>Agency for Healthcare Research and Quality</article-title>. Accessed December 30, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.hcup-us.ahrq.gov/nisoverview.jsp" ext-link-type="uri">www.hcup&#8208;us.ahrq.gov/nisoverview.jsp</ext-link></mixed-citation></ref><ref id="aogs14654-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="aogs14654-cit-0014"><string-name name-style="western"><surname>Youssefzadeh</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>McGough</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Sweeney</surname><given-names>HE</given-names></string-name>, <string-name name-style="western"><surname>Mandelbaum</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Ouzounian</surname><given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Matsuo</surname><given-names>K</given-names></string-name>. <article-title>Patient characteristics of contraception and sterilization selection at vaginal delivery</article-title>. <source>F S Rep</source>. <year>2022</year>;<volume>3</volume>:<fpage>361</fpage>&#8208;<lpage>365</lpage>.<pub-id pub-id-type="pmid">36568937</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xfre.2022.09.001</pub-id><pub-id pub-id-type="pmcid">PMC9783132</pub-id></mixed-citation></ref><ref id="aogs14654-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="aogs14654-cit-0015"><string-name name-style="western"><surname>Matsuzaki</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mandelbaum</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Sangara</surname><given-names>RN</given-names></string-name>, et al. <article-title>Trends, characteristics, and outcomes of placenta accreta spectrum: a national study in the United States</article-title>. <source>Am J Obstet Gynecol</source>. <year>2021</year>;<volume>225</volume>:<fpage>534.e1</fpage>&#8208;<lpage>534.e38</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajog.2021.04.233</pub-id><pub-id pub-id-type="pmid">33894149</pub-id></mixed-citation></ref><ref id="aogs14654-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="aogs14654-cit-0016"><string-name name-style="western"><surname>Mazza</surname><given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>Youssefzadeh</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Klar</surname><given-names>M</given-names></string-name>, et al. <article-title>Association of pregnancy characteristics and maternal mortality with amniotic fluid embolism</article-title>. <source>JAMA Netw Open</source>. <year>2022</year>;<volume>5</volume>:<elocation-id>e2242842</elocation-id>.<pub-id pub-id-type="pmid">36399343</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2022.42842</pub-id><pub-id pub-id-type="pmcid">PMC9675004</pub-id></mixed-citation></ref><ref id="aogs14654-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="aogs14654-cit-0017"><string-name name-style="western"><surname>Logue</surname><given-names>TC</given-names></string-name>, <string-name name-style="western"><surname>Wen</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Monk</surname><given-names>C</given-names></string-name>, et al. <article-title>Trends in and complications associated with mental health condition diagnoses during delivery hospitalizations</article-title>. <source>Am J Obstet Gynecol</source>. <year>2022</year>;<volume>226</volume>:<fpage>405.e1</fpage>&#8208;<lpage>405.e16</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajog.2021.09.021</pub-id><pub-id pub-id-type="pmid">34563500</pub-id></mixed-citation></ref><ref id="aogs14654-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="aogs14654-cit-0018"><string-name name-style="western"><surname>Youssefzadeh</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Tavakoli</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Panchal</surname><given-names>VR</given-names></string-name>, <string-name name-style="western"><surname>Mandelbaum</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Ouzounian</surname><given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Matsuo</surname><given-names>K</given-names></string-name>. <article-title>Incidence trends of shoulder dystocia and associated risk factors: a nationwide analysis in the United States</article-title>. <source>Int J Gynaecol Obstet</source>. <year>2023</year>;<volume>162</volume>:<fpage>578</fpage>&#8208;<lpage>589</lpage>.<pub-id pub-id-type="pmid">36707062</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijgo.14699</pub-id></mixed-citation></ref><ref id="aogs14654-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="aogs14654-cit-0019"><string-name name-style="western"><surname>Wolters</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Heimovaara</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Maggen</surname><given-names>C</given-names></string-name>, et al. <article-title>Management of pregnancy in women with cancer</article-title>. <source>Int J Gynecol Cancer</source>. <year>2021</year>;<volume>31</volume>:<fpage>314</fpage>&#8208;<lpage>322</lpage>.<pub-id pub-id-type="pmid">33649001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/ijgc-2020-001776</pub-id><pub-id pub-id-type="pmcid">PMC7925815</pub-id></mixed-citation></ref><ref id="aogs14654-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="aogs14654-cit-0020"><string-name name-style="western"><surname>Amant</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Halaska</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Fumagalli</surname><given-names>M</given-names></string-name>, et al. <article-title>Gynecologic cancers in pregnancy: guidelines of a second international consensus meeting</article-title>. <source>Int J Gynecol Cancer</source>. <year>2014</year>;<volume>24</volume>:<fpage>394</fpage>&#8208;<lpage>403</lpage>.<pub-id pub-id-type="pmid">24445819</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/IGC.0000000000000062</pub-id></mixed-citation></ref><ref id="aogs14654-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="aogs14654-cit-0021"><string-name name-style="western"><surname>Just Vinholt</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>H&#248;jrup Knudsen</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Sperling</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Frederiksen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Nielsen</surname><given-names>C</given-names></string-name>. <article-title>Platelet function tests predict bleeding in patients with acute myeloid leukemia and thrombocytopenia</article-title>. <source>Am J Hematol</source>. <year>2019</year>;<volume>94</volume>:<fpage>891</fpage>&#8208;<lpage>901</lpage>.<pub-id pub-id-type="pmid">31119762</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ajh.25512</pub-id></mixed-citation></ref><ref id="aogs14654-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="aogs14654-cit-0022"><string-name name-style="western"><surname>Smith</surname><given-names>LH</given-names></string-name>, <string-name name-style="western"><surname>Danielsen</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Allen</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Cress</surname><given-names>R</given-names></string-name>. <article-title>Cancer associated with obstetric delivery: results of linkage with the California cancer registry</article-title>. <source>Am J Obstet Gynecol</source>. <year>2003</year>;<volume>189</volume>:<fpage>1128</fpage>&#8208;<lpage>1135</lpage>.<pub-id pub-id-type="pmid">14586366</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1067/s0002-9378(03)00537-4</pub-id></mixed-citation></ref><ref id="aogs14654-bib-0023"><label>23</label><mixed-citation publication-type="book" id="aogs14654-cit-0023"><collab collab-type="authors">ICD&#8208;10</collab>
. <publisher-name>National Cancer Institute</publisher-name>. Accessed March 10, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cancercenters.cancer.gov/GrantsFunding/ICD10" ext-link-type="uri">https://cancercenters.cancer.gov/GrantsFunding/ICD10</ext-link></mixed-citation></ref><ref id="aogs14654-bib-0024"><label>24</label><mixed-citation publication-type="miscellaneous" id="aogs14654-cit-0024"><collab collab-type="authors">Basic Contraceptive Implant Coding</collab>
. <article-title>American College of Obstetricians and Gynecologists</article-title>. <year>2023</year> Accessed March 10, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.acog.org/education-and-events/publications/larc-quick-coding-guide/basic-contraceptive-implant" ext-link-type="uri">https://www.acog.org/education&#8208;and&#8208;events/publications/larc&#8208;quick&#8208;coding&#8208;guide/basic&#8208;contraceptive&#8208;implant</ext-link></mixed-citation></ref><ref id="aogs14654-bib-0025"><label>25</label><mixed-citation publication-type="miscellaneous" id="aogs14654-cit-0025"><collab collab-type="authors">Basic IUD Coding</collab>
. <article-title>American College of Obsetricians and Gynecologists</article-title>. Accessed March 10, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.acog.org/education-and-events/publications/larc-quick-coding-guide/basic-iud" ext-link-type="uri">https://www.acog.org/education&#8208;and&#8208;events/publications/larc&#8208;quick&#8208;coding&#8208;guide/basic&#8208;iud</ext-link></mixed-citation></ref><ref id="aogs14654-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="aogs14654-cit-0026"><string-name name-style="western"><surname>Fang</surname><given-names>NZ</given-names></string-name>, <string-name name-style="western"><surname>Westhoff</surname><given-names>CL</given-names></string-name>. <article-title>Update on incidence of inpatient tubal ligation and long&#8208;acting reversible contraception in the United States</article-title>. <source>Am J Obstet Gynecol</source>. <year>2022</year>;<volume>227</volume>:<fpage>477.e1</fpage>&#8208;<lpage>477.e7</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajog.2022.05.021</pub-id><pub-id pub-id-type="pmid">35569515</pub-id></mixed-citation></ref><ref id="aogs14654-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="aogs14654-cit-0027"><string-name name-style="western"><surname>Mandelbaum</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Matsuzaki</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sangara</surname><given-names>RN</given-names></string-name>, et al. <article-title>Paradigm shift from tubal ligation to opportunistic salpingectomy at cesarean delivery in the United States</article-title>. <source>Am J Obstet Gynecol</source>. <year>2021</year>;<volume>225</volume>:<fpage>399.e1</fpage>&#8208;<lpage>399.e32</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajog.2021.06.074</pub-id><pub-id pub-id-type="pmid">34181896</pub-id></mixed-citation></ref><ref id="aogs14654-bib-0028"><label>28</label><mixed-citation publication-type="miscellaneous" id="aogs14654-cit-0028"><collab collab-type="authors">How Does CDC Identify Severe Maternal Morbidity</collab>
. <article-title>Centers for Disease Control</article-title>. Accessed March 10, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/reproductivehealth/maternalinfanthealth/smm/severe-morbidity-ICD.htm" ext-link-type="uri">https://www.cdc.gov/reproductivehealth/maternalinfanthealth/smm/severe&#8208;morbidity&#8208;ICD.htm</ext-link></mixed-citation></ref><ref id="aogs14654-bib-0029"><label>29</label><mixed-citation publication-type="miscellaneous" id="aogs14654-cit-0029"><collab collab-type="authors">Europe UNECf</collab>
. <article-title>Mean age of women at birth of first child</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://w3.unece.org/PXWeb/en/Table?IndicatorCode=34" ext-link-type="uri">https://w3.unece.org/PXWeb/en/Table?IndicatorCode=34</ext-link></mixed-citation></ref><ref id="aogs14654-bib-0030"><label>30</label><mixed-citation publication-type="book" id="aogs14654-cit-0030"><collab collab-type="authors">BE MTaH</collab>
. <source>Mean age of mothers is on the rise: United States, 2000&#8211;2014</source>. NCHS data brief No. 232. <publisher-name>National Center for Health Statistics</publisher-name>.</mixed-citation></ref><ref id="aogs14654-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="aogs14654-cit-0031"><string-name name-style="western"><surname>Sweeney</surname><given-names>HE</given-names></string-name>, <string-name name-style="western"><surname>Bainvoll</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Mandelbaum</surname><given-names>RS</given-names></string-name>, et al. <article-title>Uptake of postplacental intrauterine device placement at cesarean delivery</article-title>. <source>AJOG Glob Rep</source>. <year>2023</year>;<volume>3</volume>:<elocation-id>100157</elocation-id>.<pub-id pub-id-type="pmid">36748028</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xagr.2022.100157</pub-id><pub-id pub-id-type="pmcid">PMC9898742</pub-id></mixed-citation></ref><ref id="aogs14654-bib-0032"><label>32</label><mixed-citation publication-type="book" id="aogs14654-cit-0032"><collab collab-type="authors">Producing National HCUP Estimates</collab>
. <source>Healthcare cost and utilization project</source>. <publisher-name>Agency for Healthcare Research and Quality</publisher-name> Accessed April 30, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://hcup-us.ahrq.gov/tech_assist/nationalestimates/508_course/508course_2018.jsp" ext-link-type="uri">https://hcup&#8208;us.ahrq.gov/tech_assist/nationalestimates/508_course/508course_2018.jsp</ext-link></mixed-citation></ref><ref id="aogs14654-bib-0033"><label>33</label><mixed-citation publication-type="miscellaneous" id="aogs14654-cit-0033"><article-title>The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies</article-title>. Equator Network. Accesssed March 10, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.equator-network.org/reporting-guidelines/strobe/" ext-link-type="uri">https://www.equator&#8208;network.org/reporting&#8208;guidelines/strobe/</ext-link></mixed-citation></ref><ref id="aogs14654-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="aogs14654-cit-0034"><string-name name-style="western"><surname>Smith</surname><given-names>LH</given-names></string-name>, <string-name name-style="western"><surname>Dalrymple</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Leiserowitz</surname><given-names>GS</given-names></string-name>, <string-name name-style="western"><surname>Danielsen</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Gilbert</surname><given-names>WM</given-names></string-name>. <article-title>Obstetrical deliveries associated with maternal malignancy in California, 1992 through 1997</article-title>. <source>Am J Obstet Gynecol</source>. <year>2001</year>;<volume>184</volume>:<fpage>1504</fpage>&#8208;<lpage>1512</lpage>; discussion 1512&#8208;3.<pub-id pub-id-type="pmid">11408874</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1067/mob.2001.114867</pub-id></mixed-citation></ref><ref id="aogs14654-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="aogs14654-cit-0035"><string-name name-style="western"><surname>Gompel</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ramirez</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Bitzer</surname><given-names>J</given-names></string-name>. <article-title>Contraception in cancer survivors &#8208; an expert review part I. breast and gynaecological cancers</article-title>. <source>Eur J Contracept Reprod Health Care</source>. <year>2019</year>;<volume>24</volume>:<fpage>167</fpage>&#8208;<lpage>174</lpage>.<pub-id pub-id-type="pmid">31033361</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13625187.2019.1602721</pub-id></mixed-citation></ref><ref id="aogs14654-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="aogs14654-cit-0036"><string-name name-style="western"><surname>Mansour</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Korver</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Marintcheva&#8208;Petrova</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Fraser</surname><given-names>IS</given-names></string-name>. <article-title>The effects of Implanon on menstrual bleeding patterns</article-title>. <source>Eur J Contracept Reprod Health Care</source>. <year>2008</year>;<volume>13</volume>(<issue>Suppl 1</issue>):<fpage>13</fpage>&#8208;<lpage>28</lpage>.<pub-id pub-id-type="pmid">18330814</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13625180801959931</pub-id></mixed-citation></ref><ref id="aogs14654-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="aogs14654-cit-0037"><string-name name-style="western"><surname>Graesslin</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Korver</surname><given-names>T</given-names></string-name>. <article-title>The contraceptive efficacy of Implanon: a review of clinical trials and marketing experience</article-title>. <source>Eur J Contracept Reprod Health Care</source>. <year>2008</year>;<volume>13</volume>(<issue>Suppl 1</issue>):<fpage>4</fpage>&#8208;<lpage>12</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13625180801942754</pub-id><pub-id pub-id-type="pmid">18330813</pub-id></mixed-citation></ref><ref id="aogs14654-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="aogs14654-cit-0038"><string-name name-style="western"><surname>Still</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Brennecke</surname><given-names>S</given-names></string-name>. <article-title>Melanoma in pregnancy</article-title>. <source>Obstet Med</source>. <year>2017</year>;<volume>10</volume>:<fpage>107</fpage>&#8208;<lpage>112</lpage>.<pub-id pub-id-type="pmid">29051777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1753495X17695001</pub-id><pub-id pub-id-type="pmcid">PMC5637994</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>